A new clinical test may be able to predict which biologic may be the most effective for each individual with rheumatoid ...

Rheumatoid arthritis and spondyloarthritis are long-lasting inflammatory diseases that gradually wear down joints. While ...

Lupin and Zentiva announce a license and supply agreement for the commercialization of biosimilar Certolizumab Pegol across ...

Upadacitinib demonstrated greater clinical efficacy and a comparable safety profile to adalimumab for treating RA, regardless of patients’ baseline CV risks.

Zentiva Group and global pharmaceutical company Lupin Limited, have entered into a license and supply agreement for ...

Certolizumab Pegol is indicated for the treatment of patients with rheumatoid arthritis, polyarticular juvenile idiopathic ...

The hot flashes and night sweats that plague breast cancer survivors during years-long hormone-suppressing therapy are eased ...

Lupin & Zentiva ink licensing and supply agreement for commercializing biosimilar Certolizumab Pegol: Our Bureau, Mumbai Wednesday, July 9, 2025, 16:20 Hrs [IST] Global Pharma maj ...

Articularis Rheumatology Specialists (ARS), a division of Articularis Healthcare Group (AHG), is pleased to announce the ...

Lymphatic drainage is said to help with everything from energy and immunity to cellulite and water retention. But does it ...

Vor Biopharma pivots to telitacicept with $175M funding, eyeing multi-billion potential. Risks include dilution, regulatory ...